0
Editorials |

Fluoroquinolones for Respiratory Infections : Too Valuable To Overuse

James H. Williams, Jr, MD, FCCP
Author and Funding Information

Affiliations: Orange, CA 
 ,  Dr. Williams is Adjunct Professor of Medicine, Internal Medicine, Pulmonary, and Critical Care, University of California, Irvine.

Correspondence to: James H. Williams, Jr, MD, FCCP, Internal Medicine, Pulmonary, and Critical Care, University of California, Irvine, 101 City Drive South, Orange, CA 92868; e-mail: j2willia@uci.edu



Chest. 2001;120(6):1771-1775. doi:10.1378/chest.120.6.1771
Text Size: A A A
Published online

Extract

In the current issue of CHEST (see page 2021), Guthrie has provided a broad and useful review of newer treatment options for the pathogens most commonly associated with both community-acquired pneumonia (CAP) and bronchitis, with a strong emphasis on the potential value of newer fluoroquinolones for empiric treatment. Guthrie discusses older fluoroquinolones such as ciprofloxacin (Bayer Pharmaceuticals; West Haven, CT) and levofloxacin (Ortho-McNeil Pharmaceutical; Raritan, NJ), and as newer fluoroquinolones moxifloxacin (Bayer Pharmaceuticals), gatifloxacin (Bristol-Myers Squibb; New York, NY), and trovafloxacin (Pfizer; New York, NY). He acknowledges his support by two of these pharmaceutical companies (Bayer Pharmaceuticals and Bristol-Myers Squibb).

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Antibiotics for Bacteremic Pneumonia*: Improved Outcomes With Macrolides but Not Fluoroquinolones
PubMed Articles
Guidelines
Tularaemia.
Finnish Medical Society Duodecim | 1/30/2009
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543